Corneal neovascularization and contemporary antiangiogenic therapeutics

Chih Chien Hsu, Hua Ming Chang, Tai Chi Lin, Kuo Hsuan Hung, Ke Hung Chien, Szu Yu Chen, San Ni Chen, Yan Ting Chen

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


Corneal neovascularization (NV), the excessive ingrowth of blood vessels from conjunctiva into the cornea, is a common sequela of disease insult that can lead to visual impairment. Clinically, topical steroid, argon laser photocoagulation, and subconjunctival injection of bevacizumab have been used to treat corneal NV. Sometimes, the therapies are ineffective, especially when the vessels are large. Large vessels are difficult to occlude and easily recanalized. Scientists and physicians are now dedicated to overcoming this problem. In this article, we briefly introduce the pathogenesis of corneal NV, and then highlight the existing animal models used in corneal NV research-the alkali-induced model and the suture-induced model. Most of all, we review the potential therapeutic targets (i.e., vascular endothelial growth factor and platelet-derived growth factor) and their corresponding inhibitors, as well as the immunosuppressants that have been discovered in recent years by corneal NV studies.

Original languageEnglish
Pages (from-to)323-330
Number of pages8
JournalJournal of the Chinese Medical Association
Issue number6
StatePublished - 1 Jun 2015


  • Angiogenesis
  • Antiangiogenesis
  • Corneal neovascularization
  • Immunosuppressant
  • Vascular endothelial growth factor


Dive into the research topics of 'Corneal neovascularization and contemporary antiangiogenic therapeutics'. Together they form a unique fingerprint.

Cite this